Login to Your Account



FDA Approves Polaris' SPA for ADI-PEG 20 Liver Cancer Trial

By Tom Wall


Friday, April 1, 2011
The FDA has approved Polaris Group's special protocol assessment (SPA) for a Phase III trial of the company's lead candidate, pegylated arginine deiminase (ADI-PEG 20), in patients with advanced hepatocellular carcinoma (HCC), or primary liver cancer.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription